Róisín O’Cearbhaill is a medical oncologist who serves as the Research Director of the Gynecologic Medical Oncology Service and also is the Clinical Director for Solid Tumor Malignancies, Cellular Therapy Service at Memorial Sloan Kettering Cancer Center (MSKCC), with a joint Associate Professor appointment at Weill Cornell Medical College. A committed advocate of excellence in patient care, Róisín serves as the Director of the Patient and Family Centered Care Grant initiative and she is also the Vice-Chair of the Investigational New Drug/Device Committee at MSKCC. She has extensive clinical and research experience in the treatment of gynecological cancers and has seen first-hand the benefits that access to clinical trials offers patients. Her research focuses on the development of novel targeted and immune-based approaches to improve outcomes for patients with cancer. She serves on several international committees and as the Chair of Developmental Therapeutics in NRG Oncology and vice-chair of the Clinical Practice Committee of SGO. She has received numerous awards for her work, including a Conquer Cancer Foundation Career Development award, a Young Investigator award from the Kaleidoscope of Hope Foundation, an Excellence in Research Award from MSKCC, and an Excellence in Teaching award from Weill Cornell Medical College. She is an associate editor for JAMA Network Open. Her research, incorporating cutting-edge technology such as CAR T cells, has been highlighted in Science Magazine.
WHO WE ARE
Fueled by our human health care mission, we’re an inspired team of innovators relentlessly pursuing ways to improve the lives of patients and their families.
WHAT IS human health care?
It's our way of life at Eisai — giving our first thought to patients and their families. Doing so drives us to create breakthrough solutions and medicines for them.
HOW WE BRING human health care TO LIFE
Breakthrough medicines are just the beginning. human health care sparks a multitude of ways in which we improve the lives of patients, their families and caregivers.
IT’S ONE THING TO TALK ABOUT PUTTING PATIENTS FIRST. IT’S QUITE ANOTHER TO DO IT FOR MORE THAN THREE DECADES.
Eisai came to America in 1987 with one goal in mind: Create innovative new medicines to help patients, their families and caregivers. In 2011, Eisai Canada joined in pursuing this goal. We’ve been breaking through ever since, with solutions and therapies that help improve the lives of the people we serve.
How does human health care lead to breakthrough products? The key is understanding the true needs of patients. We know in our hearts how the possibility of a breakthrough can help patients and their families keep fighting. That's why we keep fighting to discover and develop solutions.
For more information, please visit our website at www.eisai.ca
To make a difference in the lives of people through our innovative medicines, vaccines, and animal health products. We are committed to being the premier, research-intensive biopharmaceutical company and are dedicated to providing leading innovations and solutions for today and the future.